Detalhe da pesquisa
1.
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment.
Int J Mol Sci
; 25(1)2023 Dec 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38203288
2.
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents.
Eur J Haematol
; 108(6): 449-459, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-35156731
3.
Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells.
Front Immunol
; 15: 1386517, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38812504
4.
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study.
Cancer Med
; 12(10): 11838-11848, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36999931
5.
Release of IFNγ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells.
Clin Cancer Res
; 28(14): 3141-3155, 2022 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35349670
6.
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia.
Front Oncol
; 11: 728613, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34660293
7.
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia.
J Oncol
; 2019: 5985923, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31827512